PharmMD, a Brentwood, Tenn.-based provider of medication therapy management (MTM) services, raised $8.8m in capital from The Riverside Company and FCA Ventures IV, a fund of Clayton Associates.
The company is focused on analyzing both aggregate and patient-specific data to identify trends and conflicts to positively impact patient health and contain costs.
According to Bo Bartholomew, co-founder and CEO of PharmMD, this new funding equips the company to continue to expand.
The board of directors of the company will add Brian Sauer, Vice President for Riverside, and Jeff Goodman, Operating Partner at Riverside, who will also serve as the new chairman.
FinSMEs
11/12/2009